243 related articles for article (PubMed ID: 16245686)
21. Initial failure in myoblast transplantation therapy has led the way toward the isolation of muscle stem cells: potential for tissue regeneration.
Urish K; Kanda Y; Huard J
Curr Top Dev Biol; 2005; 68():263-80. PubMed ID: 16125002
[TBL] [Abstract][Full Text] [Related]
22. Facioscapulohumeral dystrophy myoblasts efficiently repair moderate levels of oxidative DNA damage.
Bou Saada Y; Dib C; Dmitriev P; Hamade A; Carnac G; Laoudj-Chenivesse D; Lipinski M; Vassetzky YS
Histochem Cell Biol; 2016 Apr; 145(4):475-83. PubMed ID: 26860865
[TBL] [Abstract][Full Text] [Related]
23. Becker's muscular dystrophy aggravating facioscapulohumeral muscular dystrophy--double trouble as an explanation for an atypical phenotype.
Rudnik-Schöneborn S; Weis J; Kress W; Häusler M; Zerres K
Neuromuscul Disord; 2008 Nov; 18(11):881-5. PubMed ID: 18684626
[TBL] [Abstract][Full Text] [Related]
24. Hypomethylation is restricted to the D4Z4 repeat array in phenotypic FSHD.
de Greef JC; Wohlgemuth M; Chan OA; Hansson KB; Smeets D; Frants RR; Weemaes CM; Padberg GW; van der Maarel SM
Neurology; 2007 Sep; 69(10):1018-26. PubMed ID: 17785671
[TBL] [Abstract][Full Text] [Related]
25. Satellite cell dysfunction contributes to the progressive muscle atrophy in myotonic dystrophy type 1.
Thornell LE; Lindstöm M; Renault V; Klein A; Mouly V; Ansved T; Butler-Browne G; Furling D
Neuropathol Appl Neurobiol; 2009 Dec; 35(6):603-13. PubMed ID: 19207265
[TBL] [Abstract][Full Text] [Related]
26. RAGE-NF-kappaB pathway activation in response to oxidative stress in facioscapulohumeral muscular dystrophy.
Macaione V; Aguennouz M; Rodolico C; Mazzeo A; Patti A; Cannistraci E; Colantone L; Di Giorgio RM; De Luca G; Vita G
Acta Neurol Scand; 2007 Feb; 115(2):115-21. PubMed ID: 17212615
[TBL] [Abstract][Full Text] [Related]
27. Facioscapulohumeral muscular dystrophy: do neurotrophins play a role?
Angelucci F; Colantoni L
Muscle Nerve; 2010 Jan; 41(1):120-7. PubMed ID: 19813193
[TBL] [Abstract][Full Text] [Related]
28. Novel mitochondrial tRNA Leu(CUN) transition and D4Z4 partial deletion in a patient with a facioscapulohumeral phenotype.
Filosto M; Tonin P; Scarpelli M; Savio C; Greco F; Mancuso M; Vattemi G; Govoni V; Rizzuto N; Tupler R; Tomelleri G
Neuromuscul Disord; 2008 Mar; 18(3):204-9. PubMed ID: 18343111
[TBL] [Abstract][Full Text] [Related]
29. The mitotic clock in skeletal muscle regeneration, disease and cell mediated gene therapy.
Mouly V; Aamiri A; Bigot A; Cooper RN; Di Donna S; Furling D; Gidaro T; Jacquemin V; Mamchaoui K; Negroni E; Périé S; Renault V; Silva-Barbosa SD; Butler-Browne GS
Acta Physiol Scand; 2005 May; 184(1):3-15. PubMed ID: 15847639
[TBL] [Abstract][Full Text] [Related]
30. Correction of the FSHD myoblast differentiation defect by fusion with healthy myoblasts.
Dib C; Bou Saada Y; Dmitriev P; Richon C; Dessen P; Laoudj-Chenivesse D; Carnac G; Lipinski M; Vassetzky YS
J Cell Physiol; 2016 Jan; 231(1):62-71. PubMed ID: 26218298
[TBL] [Abstract][Full Text] [Related]
31. Characterization of proliferating human skeletal muscle-derived cells in vitro: differential modulation of myoblast markers by TGF-beta2.
Stewart JD; Masi TL; Cumming AE; Molnar GM; Wentworth BM; Sampath K; McPherson JM; Yaeger PC
J Cell Physiol; 2003 Jul; 196(1):70-8. PubMed ID: 12767042
[TBL] [Abstract][Full Text] [Related]
32. Ex vivo generation of mature and functional human smooth muscle cells differentiated from skeletal myoblasts.
Le Ricousse-Roussanne S; Larghero J; Zini JM; Barateau V; Foubert P; Uzan G; Liu X; Lacassagne MN; Ternaux B; Robert I; Benbunan M; Vilquin JT; Vauchez K; Tobelem G; Marolleau JP
Exp Cell Res; 2007 Apr; 313(7):1337-46. PubMed ID: 17362928
[TBL] [Abstract][Full Text] [Related]
33. Alteration of expression of muscle specific isoforms of the fragile X related protein 1 (FXR1P) in facioscapulohumeral muscular dystrophy patients.
Davidovic L; Sacconi S; Bechara EG; Delplace S; Allegra M; Desnuelle C; Bardoni B
J Med Genet; 2008 Oct; 45(10):679-85. PubMed ID: 18628314
[TBL] [Abstract][Full Text] [Related]
34. [Cell therapy for Duchenne muscular dystrophy].
Zhou C; Zhang C
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):659-61. PubMed ID: 17160947
[TBL] [Abstract][Full Text] [Related]
35. Skeletal muscle regeneration in facioscapulohumeral muscular dystrophy is correlated with pathological severity.
Banerji CRS; Henderson D; Tawil RN; Zammit PS
Hum Mol Genet; 2020 Sep; 29(16):2746-2760. PubMed ID: 32744322
[TBL] [Abstract][Full Text] [Related]
36. Neuromuscular electrical stimulation training: a safe and effective treatment for facioscapulohumeral muscular dystrophy patients.
Colson SS; Benchortane M; Tanant V; Faghan JP; Fournier-Mehouas M; Benaïm C; Desnuelle C; Sacconi S
Arch Phys Med Rehabil; 2010 May; 91(5):697-702. PubMed ID: 20434605
[TBL] [Abstract][Full Text] [Related]
37. Age dependence of the human skeletal muscle stem cell in forming muscle tissue.
Schäfer R; Knauf U; Zweyer M; Högemeier O; de Guarrini F; Liu X; Eichhorn HJ; Koch FW; Mundegar RR; Erzen I; Wernig A
Artif Organs; 2006 Mar; 30(3):130-40. PubMed ID: 16480387
[TBL] [Abstract][Full Text] [Related]
38. Localization of 4q35.2 to the nuclear periphery: is FSHD a nuclear envelope disease?
Masny PS; Bengtsson U; Chung SA; Martin JH; van Engelen B; van der Maarel SM; Winokur ST
Hum Mol Genet; 2004 Sep; 13(17):1857-71. PubMed ID: 15238509
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic challenges in facioscapulohumeral muscular dystrophy.
Sacconi S; Salviati L; Bourget I; Figarella D; Péréon Y; Lemmers R; van der Maarel S; Desnuelle C
Neurology; 2006 Oct; 67(8):1464-6. PubMed ID: 17060574
[TBL] [Abstract][Full Text] [Related]
40. Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy.
van Overveld PG; Enthoven L; Ricci E; Rossi M; Felicetti L; Jeanpierre M; Winokur ST; Frants RR; Padberg GW; van der Maarel SM
Ann Neurol; 2005 Oct; 58(4):569-76. PubMed ID: 16178028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
